Aspergillus fumigatus is commonly found in the airways of patients with cystic fibrosis (CF), and allergic bronchopulmonary aspergillosis (ABPA) is the most recognized associated clinical condition. However, accurate diagnosis remains challenging, and there is a paucity of clinical trials to guide clinical management of fungal disease. The aim of this survey was to assess the variability in current practice across the UK in diagnosis and management of fungal lung disease in CF patients. A 21 question anonymous online survey was sent to 94 paediatric and adult CF consultants in the UK. The response rate was 60.6% (32 adult physicians, 25 pediatricians) with 55 full and 2 partially completed surveys. For a first diagnosis of ABPA 20 (35.1%) treat with prednisolone alone, 38 (66.7%) use prednisolone with itraconazole and 2 (3.5%) choose voriconazole. Only 5 (8.8%) treat with prednisolone alone for a 1st relapse, 33 (58%) used prednisolone with itraconazole. To reduce treatment, 21 (36.8%) decrease steroids to zero over time and maintain azole therapy, 18 (31.6%) stop the azole and steroid after a fixed time, and 5 (8.8%) stop the azole after a fixed time and maintain a small steroid dose. Thirty-eight (66.7%) respondents believe Aspergillus colonization of the airway can cause clinical deterioration, and 37 (66.1%) would treat this. Scedosporium apiospermum infection has been diagnosed and treated by 35 (61.4%) of respondents. Results of this survey highlight the variance in clinical practice and the limited evidence available to guide management of fungal infection in CF.
Introduction
People with cystic fibrosis (PWCF) are extremely vulnerable to respiratory tract infections. Although infections are mainly bacterial in origin, with particular emphasis on Pseudomonas aeruginosa, fungal species are also commonly cultured. Aspergillus fumigatus is the most common fungal species found in the sputum of PWCF, with an estimated prevalence of 6-57%. [1] [2] [3] [4] Allergic bronchopulmonary aspergillosis (ABPA) is the main clinical manifestation. However, asymptomatic colonization, Aspergillus bronchitis and Aspergillus sensitization are also recognized as part of the disease spectrum. 2, 5, 6 The most widely accepted criteria used to diagnose ABPA in PWCF were proposed at the 2003 CF Foundation Consensus Conference. 7 However since 2005, 50%
of publications regarding ABPA have used alternative diagnostic criteria and the prevalence of ABPA differed when studies were stratified according to the criteria used for diagnosis. 8 Diagnosis of Aspergillus sensitization and bronchitis can also be challenging due to an overlap in symptoms and diagnostic markers. The prevalence of Aspergillus bronchitis in adult CF patients has been estimated at 30% and sensitization to Aspergillus between 15% and 65%. 6, 8 Despite the prevalence of fungal related infection in PWCF there is a paucity of randomised controlled trials (RCTs) to guide diagnosis and management. Although corticosteroids are the mainstay of treatment for ABPA, there is little evidence to guide dosing and duration of treatment, despite the significant associated side effects. 9 A 2014 systematic review of ABPA treatment (in patients with and without CF) demonstrated limited evidence for anti-fungal therapy. However, a trend toward improved symptoms, frequency of exacerbations, and lung function was observed. 10 The Infectious Diseases Society of America (IDSA) 2016 guidelines for treatment of ABPA and Aspergillus bronchitis make weak recommendations due to low quality evidence. 11 There are no evidencebased guidelines on the diagnosis and management of other less commonly isolated fungi such as Scedosporium apiospermum.
Our aim was to obtain data on how respiratory tract fungal infections are diagnosed, monitored and managed in UK CF centers.
Methods
A 21 question anonymous electronic survey was emailed to all known 94 consultants affiliated with recognized UK CF centers. The survey explored the criteria used to diagnose and screen for ABPA, how ABPA is treated (and on first and second relapse), treatment duration/reduction, and routine monitoring carried out while on treatment. We asked if CF physicians would treat Aspergillus colonization, Aspergillus bronchitis, or Aspergillus sensitization not meeting ABPA criteria. Finally, we requested details of experience in managing Scedosporium apiospermum and their views on RCTs in ABPA, non-ABPA Aspergillus conditions, and other fungal infections. We compared adult to pediatric responses using χ 2 analysis.
Results
The response rate was 60.6% (55 fully and 2 partially completed). 
Treatment
In the treatment of a first diagnosis of ABPA, 38 (66.7%) physicians would use prednisolone alongside itraconazole (19 (33.7%) using capsules and 19 (33.7%) using itraconazole liquid). Twenty (35.1%) respondents reported using prednisolone alone. Prednisolone with voriconazole was only chosen by 2 (3.5%). Unfortunately to allow additional comments participants could check more than one answer. Additional reported treatments included methylprednisolone, posaconazole, nebulized amphotericin, and IV caspofungin.
There was a significant difference in adult and paediatric physician treatment choices. For a first diagnosis of ABPA, 15 (47%) of adult physicians treat with prednisolone alone, compared with just 5 (20%) pediatricians (P < .0001). Prednisolone with itraconazole capsules was chosen by 13 (41%) adult physicians and 6 (24%) pediatricians. Prednisolone with itraconazole liquid was more Figure 1 . This figure shows the differences between adult physicians (n = 32) and pediatricians (n = 25) in their treatment choices for ABPA diagnosed for the first time. Treatment choices consisted of prednisolone alone (47% adult physicians vs 20% pediatricians used this regimen, p<0.0001), prednisolone (pred) and intraconazole capsules (41% adult physicians vs 24% pediatricians) or itraconazole liquid (12.5% adult physicians vs 60% pediatricians), pred and voriconazole (was chosen only by 8% of pediatricians). popular among pediatricians with 15 (60%) choosing this as first line treatment, compared to 4 (12.5%) adult physicians. Finally, no adult physicians reported using voriconazole but 2 (8%) pediatricians would use prednisolone with voriconazole ( Fig. 1) .
For a first relapse of ABPA, 33 (58%) reported using prednisolone alongside itraconazole (19 (33.3%) using liquid and 14 (24.6%) using capsules). Prednisolone with voriconazole was chosen by 7 (12.3%), prednisolone alone was chosen by 5 (8.8%) respondents, and 4 (7%) physicians stated they would use prednisolone and posaconazole.
There was a significant difference in the adult and paediatric physician choices in the management of a first relapse. Four (12.5%) adult physicians chose prednisolone alone, compared with only 1 (4%) pediatrician (P < .0001). Prednisolone and itraconazole was used by 20 (62.5%) of the adult physicians (11 choosing capsules and 9 liquid), compared to 13 (52%) of the pediatricians (3 (12%) choosing capsules and 10 (40%) liquid). Prednisolone and voriconazole was used by 5 (16%) adult physicians and 2 (8%) pediatricians (Fig. 2) .
For a second relapse of ABPA, 19 (33.3%) used prednisolone with voriconazole. Prednisolone with itraconazole was chosen by 15 (26%). Four (7%) respondents stated they would choose prednisolone plus posaconazole, 4 (7%) would treat the same as a first relapse, 3 (5%) reported the use of methylprednisolone, and 3 (5%) would more likely use voriconazole. Prednisolone alone was reported as treatment of choice by one physician.
Nebulized Amphotericin and Omalizumab
Thirty-three (57.9%) respondents have had experience of using nebulized amphotericin, while 32 (56.1%) had experience of Omalizumab. Eleven (19.3%) respondents had used neither. This figure shows the differences between adult physicians (n = 32) and pediatricians (n = 25) in their treatment choices for a first relapse of ABPA. Treatment choices consisted of prednisolone alone (12.5% adult physicians vs 4% pediatricians used this regimen, p<0.0001), prednisolone (pred) and intraconazole capsules (34% adult physicians vs 12% pediatricians) or itraconazole liquid (28% adult physicians vs 40% pediatricians), pred and voriconazole (16% adult physicians vs 8% pediatricians).
Treatment monitoring
All 57 (100%) physicians would monitor total serum IgE, 47(82.5%) specific Aspergillus IgE, and 28 (49.1%) specific Aspergillus immunoglobulin G (IgG). Spirometry is monitored by 54 (94.7%) and chest X-ray by 38 (66.7%). Additionally, five physicians reported monitoring eosinophil count, and two stated they would monitor a chest X-ray only if there were X-ray changes at the time of diagnosis.
The majority of physicians, 48 (84%), monitor azole levels if used in treatment.
Reducing treatment when clinically stable on steroid and azole therapy Twenty-one (36.8%) would reduce steroids to zero over time and maintain azole therapy, 18 (31.6%) would stop the azole and steroid after a fixed time, and 5 (8.8%) would stop the azole after a fixed time (e.g., 3 or 6 months) and maintain a small steroid dose. Additional comments were permitted to obtain further detail, 10 would reduce steroid to zero then stop the azole later (3 would stop the azole at 3-6 months and 7 based the timescale of stopping the azole on each patient's response and stability) (Fig. 3) .
Non-ABPA Aspergillus conditions
Thirty-eight (66.7%) respondents believed that chronic Aspergillus colonization of the airways can cause clinical deterioration, whereas 15 (26.3%) were unsure. Thirtyseven (66.1%) respondents reported they would treat this, 3 (5.4%) would not, and 16 (28.6%) were unsure. Aspergillus bronchitis has been treated by 42 respondents (73.7%) and 6 (10.5%) have not. Thirty (52.6%) physicians believe that Aspergillus sensitization (not meeting ABPA criteria) of the airways can cause clinical deterioration, 3 (5.3%) did not, 
Scedosporium apiospermum
Thirty-five (61.4%) had experience in treating patients with Scedosporium apiospermum, and 22 (38.6%) did not. Voriconazole was the treatment of choice by 21 (46.7%), and 13 (28.9%) would use prednisolone and voriconazole. Four physicians stated they would use posaconazole to treat Scedosporium apiospermum.
Further research
Forty-six (80.7%) respondents believed that RCTs were required in ABPA, 43 (75.4%) for non-ABPA Aspergillus conditions and 33 (57.9%) for other fungi.
However challenges were noted, 'very difficult due to diverse diagnostic criteria', 'this would be difficult as ABPA is difficult to characterize at least in pediatrics' and, 'we have attributed serious and rapid clinical decline to a variety of fungal infections that fall outside guideline ABPA diagnostic criteria.'
Discussion
This survey was designed to gain an overview of the diagnosis and clinical management of fungal disease in UK CF Centers and determine some of the challenges that arise with recurrent disease. To our knowledge this is the largest survey carried out in the United Kingdom to date. A smaller and less comprehensive survey in 2001 also reported variability in diagnostic criteria and treatment. 12 Aspergillus fumigatus can cause a spectrum of hypersensitivity responses and disease phenotypes. A recent review described a wide range of criteria used in the diagnosis of ABPA. 8 Our results show that total serum IgE was the most commonly used test (98%), but there is individual variability in immune response which results in difficulty defining a value to be used in diagnostic criteria. 13 Interestingly, 61% have access to galactomannan testing in their local laboratory, but only 14% use it to aid in diagnosis. This may be due to physician uncertainty in the interpretation of results and the implication for treatment. Serum galactomannan testing has a low sensitivity, 14, 15 which may limit its use as a diagnostic tool. Also there are conflicting reports of the usefulness of sputum galactomannan testing as a diagnostic aid in Aspergillus related infection. 3, 16 However, sputum galactomannan with Aspergillus real-time polymerase chain reaction (PCR) and serological tests can be used in classifying Aspergillus disease phenotypes.
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Skin prick testing for an immediate IgE mediated response is a sensitive marker of Aspergillus sensitization and along with an elevated total serum IgE is useful in the diagnosis of ABPA. 9 Although part of the 2003 Consensus Conference recommendations, only 12.3% of our responding physicians employ it. The reasons were not documented, but this may have been due to test availability and a positive result is not specific for ABPA. 17 The majority of respondents (72%) use peripheral blood eosinophilia as a diagnostic aid. This is widely available and inexpensive but has limited value in ABPA diagnosis. 7, 18 Newer biomarkers have been evaluated, but are not yet established or widely used. IgE specific to certain recombinant Aspergillus allergens, Thymus activation-regulated chemokine (TARC/CCL17) and basophil activation testing may become useful biomarkers in diagnosis and for distinguishing ABPA from non-ABPA Aspergillus related conditions. 13, 19, 20 There was also considerable variation in ABPA treatment practices. For a first diagnosis, the most common regime was prednisolone and itraconazole, (66.7%) followed by prednisolone alone (35.1%). As the survey progressed from first diagnosis to recurrent ABPA relapse, the number of additional comments increased, highlighting an increasing variation in practice in more complex cases of ABPA. Additional differences in adult and pediatric treatment regimens have not been reported before. Adult physicians were more likely to use prednisolone alone to treat a first diagnosis of ABPA whereas pediatricians prefer the addition of itraconazole.
There have been RCTs of itraconazole in ABPA for patients with asthma. 21 Antifungal treatment has considerable side effects, drug interactions, and challenges with bioavailability. 22 Drug monitoring is recommended, 11 but 23% of respondents do not monitor levels. Subtherapeutic azole levels may play a role in the development of azole resistance. Case reports described azole resistance in ABPA and Aspergillus bronchitis in 2009. 23 In a study of 519 patients with Aspergillus fumigatus isolates there was a 5% frequency of itraconazole resistance with 65% crossresistance to voriconazole. 24 In a CF study, a 4.6% rate of itraconazole resistance was noted, and all of these isolates also showed reduced susceptibility to posaconazole. 25 Higher rates of azole resistance were also found in those recently exposed to itraconazole. 25 The CF Trust laboratory standards currently recommend susceptibility testing when there is repeated isolation of Aspergillus sp. despite longterm azole treatment. 26 Pulsed methylprednisolone, caspofungin, and nebulized amphotericin are utilized in more complex cases. This is based on clinical experience rather than significant published data. There was variation in treatment practice when PWCF were clinically stable. The majority response was to reduce the steroid to zero and maintain the azole. This would be stopped at a later date, usually at 3-6 months, but others stating 'gradually' and 'as per clinical response'. With the potential for relapse balanced with toxicity of prolonged treatment, there is a pressing need for guidance in both treatment and duration.
Omalizumab is a monoclonal anti-IgE antibody that can improve control in allergic asthma. 27 An RCT in PWCF was prematurely terminated due to challenges with recruitment and retention; however, a case report series described an improvement in FEV 1 and symptoms with a reduction in steroid use in children. 28 Over half of our respondents have previous experience of using it, and it may be beneficial to collate this experience for regimen guidance in complex cases. It is increasingly recognized that Aspergillus species can cause clinical deterioration in PWCF even when ABPA diagnostic criteria are not fulfilled. 2 Thirty-six percent of our respondents reported that they would treat a clinical deterioration from Aspergillus colonization, 49% would consider treating Aspergillus sensitization, and 74% would treat Aspergillus bronchitis. Aspergillus sensitization is defined as a positive skin prick test to Aspergillus antigens or an elevated serum Aspergillus IgE level. 1, 8 An observational study over 2 years described a decline in FEV 1 and an increase in IV antibiotic days for patients sensitised to Aspergillus. Scedosporium apiospermum is a saprophytic filamentous fungus and is the second most frequent fungus to colonize PWCF. 31, 32 Case reports suggest that it may have a pathogenic role in CF. 33, 34 However, Parize et al. did not demonstrate a clinical deterioration with colonization or sensitization. 35 There was uncertainty among survey respondents regarding the significance and treatment of Scedosporium; however, the majority (61.4%) have some experience in treating patients. This survey has highlighted a variety of challenges in CF respiratory tract fungal disease. Designing and executing prospective RCTs in fungal disease will be challenging; therefore, a rethink of trial design may be required. Perhaps exploring registry data, CF centers clustered for comparative treatment effectiveness, or adaptive trial designs are some possibilities. However, we must rise to the challenge of understanding our treatment choices and establishing an evidence base for them.
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